London, United Kingdom
London, United Kingdom

AstraZeneca plc is a British multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by 2012 prescription drug sales and has operations in over 100 countries.AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Sweden-based Astra AB and the UK-based Zeneca Group . It has made numerous corporate acquisitions, including of Cambridge Antibody Technology , MedImmune , and Spirogen .AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalisation of approximately £54.8 billion as of 1 August 2014, the sixth largest of any company with a primary listing on the London Stock Exchange. It has secondary listings on the New York Stock Exchange and the OMX exchange. Wikipedia.


Time filter

Source Type

Patent
Amylin Pharmaceuticals Inc. and Astrazeneca | Date: 2017-01-04

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimers disease, fatty liver disease, short bowel syndrome, Parkinsons disease, cardiovascular disease, and other and disorders of the central nervous system.


The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene. A further aspect of the invention relates to methods of treatment that may overcome such resistance mechanisms, involving the use of an EGFR inhibitor in combination with a MEK inhibitor for the treatment of cancers involving an NRAS mutation selected from E63K, G12V, G12R, G12A, G12D, G12S and G12C, and/or cancel- involving a gain of copy number of NRAS gene.


A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.


Patent
Astrazeneca | Date: 2017-03-22

The present invention discloses a dry powder inhaler (1) comprising a housing (10, 10) with: an air supply channel (100) fluidly connected with an air inlet opening (101, 102) of the housing (10, 10); a single circulation chamber (140) for deagglomeration of a powder formulation, wherein the circulation chamber (140) is fluidly connected and/or connectable with the air supply channel (100), and wherein the circulation chamber (140) is arranged downstream of the air supply channel (100); a mouthpiece (13) fluidly connected with the circulation chamber (140) via an outlet (143) of the circulation chamber (140), wherein the mouthpiece (13) is arranged downstream of the circulation chamber 140). The dry powder inhaler according to the present invention is characterised in that the dry powder inhaler (1) contains only one single dose of the powder formulation and in that during storage of the powder formulation the powder formulation is in direct contact with the housing (10, 10).


Patent
Astrazeneca and Cancer Research Technology Ltd | Date: 2017-04-05

The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.


A solid, rapidly gelling oral pharmaceutical dosage form, as well as an aqueous formulation prepared thereof, comprising a) an acid sensitive proton pump inhibitor as active ingredient distributed in a multitude of enteric coated pellets, and b) a suspension modifying granulate. Furthermore, the invention relates to an improved process for the manufacture and the use of such formulation in medical treatment, including prevention of gastrointestinal disorders in humans.


Patent
Astrazeneca | Date: 2017-06-07

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A-related pathologies such as Downs syndrome, - amyloid angiopathy such as, but not limited to, cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (mild cognitive impairment), Alzheimers disease, memory loss, attention deficit symptoms associated with Alzheimers disease, neurodegeneration associated with diseases such as Alzheimers disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinsons disease.


The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.


There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.


Patent
Astrazeneca | Date: 2016-11-08

The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R^(1), R^(2 )and R^(3 )have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.

Loading Astrazeneca collaborators
Loading Astrazeneca collaborators